tbuckley/cabot-search huggingface dataset:
Clarithromycin Therapy for Mycobacterium avium Complex Bacteremia
Authors: Daniel M. Musher
Journal: Annals of Internal Medicine (1995)

Letters15 July 1995Clarithromycin Therapy for Mycobacterium avium Complex BacteremiaDaniel M. MusherDaniel M. MusherSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-2-199507150-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A new antimicrobial agent is used to treat a febrile, infectious condition. Three groups of patients are treated with a range of dosages. In all groups, fever is significantly reduced compared with baselines. The reduction is greatest in persons receiving the highest dose, but so is the mortality.An objective reader cannot help but raise two questions: 1) What is the rate of survival in the untreated controls? and 2) What is the effect of treatment with nonantimicrobial antipyretic agents such as cyclooxygenase inhibitors? In the recent article on treatment of M. avium complex infection in persons ...References1. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Google Scholar2. Goldberger M, Masur H. Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems (Editorial). Ann Intern Med. 1995; 121:974-6. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 July 1995Volume 123, Issue 2Page: 154-155KeywordsAIDSAntimicrobial resistanceAntimicrobialsBacteremiaDrug therapyDrugsFeversMortalityMycobacterium avium complexQuality of life Issue Published: 15 July 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
False-Positive Serologic Tests for Human T-Cell Lymphotropic Virus Type I Among Blood Donors Following Influenza Vaccination, 1992
Journal: JAMA (1993)

From October 31 through December 15, 1991, 10 blood donors to the American Red Cross Blood Services, Badger Region (ARCBS), were found to have false-positive screening enzyme-linked immunosorbent assays (ELISAs) for antibodies to two or more of the following viruses: human immunodeficiency virus type 1 (HIV-1), human T-cell lymphotrophic virus type 1 (HTLV-I), and hepatitis C virus (HCV). An investigation by the Division of Health, Wisconsin Department of Health and Social Services (WDOH), and the ARCBS indicated that the risk for false-positive reactivity was associated with antecedent receipt of influenza vaccine formulated for the 1991-92 season. In March 1992, the ARCBS began use of newly available ELISAs for anti-HIV (HIVAB, HIV-1/HIV-2 (rDNA) EIA [Abbott Laboratories, Abbott Park, Illinois]) and anti-HCV (HCV 2.0 ELISA [Ortho Diagnostic Systems, Raritan, New Jersey]), while continuing to test with the ELISA for anti-HTLV-I [HTLV-I ELISA (Abbott Laboratories) used in 1991. From January 1 through October 13, 1992, the ARCBS identified 19 blood donors with repeatedly reactive ELISAs for HTLV-I. However, from October 14 through November 10, 15 false-positive ELISAs for HTLV-I were reported by the ARCBS to the WDOH. As a result of this increase, the ARCBS conducted a case-control study to assess the relation between influenza vaccination and testing positive for HTLV-I. This report summarizes the results of the study.
Abstract 4601: Phospholipid and enzyme antibodies for the evaluation of novel cancer biomarkers
Authors: Cameron Day, Paul Neilsen
Journal: Cancer Research (2019)

Abstract Sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) are well characterized bioactive phospholipids with migratory and proliferative effects in cancer progression. Recent studies show that the enzyme responsible for production of S1P, sphingosine kinase (SK), is upregulated in a variety of cancers, S1P is a tumorigenic growth factor, and there is an association between S1P levels in cancer patients and their resulting clinical outcomes. Similarly, LPA has been shown to drive angiogenesis and tumor invasion. LPA receptors and the LPA synthesizing enzyme autotaxin (ATX) have also been shown to be abnormally expressed in at least ovarian and breast tumors. S1P, SK, LPA, and ATX therefore represent potential biomarkers for the detection and staging of cancer. We have now characterized anti-S1P and anti-LPA antibodies for basic immunochemical methods in cells and ovary tissue. These antibodies were previously developed as anti-cancer immunotherapeutic agents. Here we highlight the potential for these reagents as bonafide cancer biomarkers for S1P and LPA. Citation Format: Cameron Day, Paul Neilsen. Phospholipid and enzyme antibodies for the evaluation of novel cancer biomarkers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4601.
Rectoscopie. Sigmoidoscopie: Traité d'endoscopie recto-colique.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Game Is Afoot
Authors: Nicholas Yozamp, Julia Charles, Hina Shah, Anand Vaidya, J. Carl Pallais
Journal: New England Journal of Medicine (2020)

A 63-year-old woman was referred to the endocrinology department for consultation regarding multiple fractures. Her chief concerns were progressively worsening pain in both ankles and difficulty walking. She needed crutches or a cane for support. . . .
Cryptic stage of sleeping sickness trypanosome developing in choroid plexus epithelial cells.
Authors: M Abolarin, D Evans, G Tovey, W Ormerod
Journal: BMJ (1983)

Electronmicrographs of the choroid plexus from rats infected with Trypanosoma brucei rhodesiense showed that trypomastigotes from the perivascular spaces may penetrate and undergo multiple division in the ependymal cells which locally constitute the blood-brain barrier.Progressive degeneration of the ependymal cell liberates trypomastigotes back into the perivascular space, from which re-entry into the blood may occur.Re-entry to the blood does not take place from any tissues other than the brain and its membranes.
From the editors
Authors: Elaine Bell, Lucy Bird, Kirsty Minton, Olive Leavy, Rachel David, Isobel Barry, Craig Nicholson, Man Tse, Gillian Young, Simon Bradbrook, Susanne Harris, Vicky Summersby, Patrick Managing, Judith Shadwell, Simon Fenwick, Natalie Smith, Laura Firman, Jacques Smit, Deborah Anthony, Marketing Managers, Tim Redding, Leah Rodriguez
Journal: Nature reviews. Immunology (2009)
Proximal Chiasma Localization within an Interstitial Chromosome Segment, a Likely Correlate of Adjacent-2 Segregation of Translocation Causing Multivalents in the Mouse
Authors: P. de Boer
Journal: Environmental Health Perspectives (1979)

Two T7OH/+ translocation-carrying male mice were used in an investigation into the relation between the segregation pattern of the translocation caused multivalent at anaphase I and the position of the only chiasma in a long interstitial segment. Moreover, the relation between meiotic stage (from early diakinesis to metaphase I) and chiasma movement was assessed. It appeared that pronounced movement of a chiasma within the multivalent was linked with chiasma terminalization in an adjacent segment, either on the same side of the translocation breakpoint or on the other side. On summing the CIV and CIII+I configurations (making up 97.9% of all configurations found) and focusing on the multivalents from late meiotic cells, 41.3% had a proximal chiasma in the long interstitial segment of the multivalent. In total, a percentage of 33.5% of all secondary spermatocytes were characteristic of adjacent-2 segregation (i.e., homologous centromeres move to the same pole at anaphase I). Results obtained with T7OH translocation trisomics, which are briefly discussed in this paper, confirm the tendency of proximal chiasma frequencies in late meiotic cells to coincide with the frequency of absence of homologous centromere separation within the T7OH translocation multivalent. The importance of this phenomenon for normal bivalent behavior during anaphase I is considered.
Thrombolytic therapy of patients with acute myocardial infarction
Authors: R. C. Schlant
Journal: JAMA (1990)

In this issue ofThe Journal, Naylor and Jaglal<sup>1</sup>report the results of their meta-analysis of patients with acute myocardial infarction who were enrolled in seven randomized control trials of thrombolytic therapy with either tissue plasminogen activator or streptokinase between March 1982 and November 1987. The authors did a meta-analysis of the number of procedures (cardiac catheterization, coronary angioplasty, or surgical coronary revascularization) performed within 6 weeks of myocardial infarction in the patients in each study treated either with or without thrombolytic therapy. Overall, in the seven trials there was a relative increase of 80% in the number of revascularization procedures (angioplasty or bypass surgery) performed on the patients treated with thrombolytic therapy; the relative increase in the number of procedures was higher in patients treated with tissue plasminogen activator than in patients treated with streptokinase. A similar increase in coronary revascularization procedures after thrombolytic therapy for myocardial infarction
LAW AND MEDICINE
Authors: William B. Smith
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intrauterine contraceptives. An unusual complication
Authors: P. J. Seward
Journal: JAMA (1965)

INTRAUTERINE contraceptive devices have provoked controversy over their mode of action, efficacy, and side effects. Perforations of the uterine wall are apparently rare, but there are reported cases in which a ring has been found outside the uterus accompanied by few or relatively minor symptoms.<sup>1</sup>Tietze and Lewit<sup>2</sup>reported, in a study of 23,602 cases, that there were 24 uterine perforations. Seventeen of these involved the Birnberg bow. Price<sup>3</sup>reported a case in which a Gräfenberg ring had eroded through some two thirds of the uterine wall and a loop of ileum had passed through the ring resulting in intestinal obstruction. Our case is similar to the one reported by Price. <h3>Report of a Case</h3> A 33-year-old woman was admitted to Rockford Memorial Hospital on July 31, 1965, because of acute abdominal pain which began in the epigastrium approximately seven hours prior to admission. This pain became
THE FUNCTION OF THE COLOSTRUM
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Team player
Authors: Brian Devitt
Journal: Annals of Internal Medicine (2014)

Ad Libitum18 March 2014Team playerBrian Devitt, MDBrian Devitt, MDFrom Toronto, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M13-2832 Audio Reading - “Team player” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Team player," by B. Devitt. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The biting whiff of Wintergreen permeates the room,Aluminium studs grate the muddy, tiled floor,Clouds of breath float like exhaust fumes on the frigid air,A warm glow radiates from their restive, sweaty frames,As white knuckles bind tightly fifteen into one.Amidst the cacophony of noise an eerie silence descends,Stares supplant words, telepathically vowing ‘never to take a backward step’,The crescendo of raucous clamor erupts as kickoff draws near,Chest-beating, feet-stamping, finger-wagging, back-slapping,The scene is set, bodies on the line.Bodies hurtle by tracking the booted ... Author, Article, and Disclosure InformationAffiliations: From Toronto, Ontario, Canada.Current Author Address: Brian Devitt, MD; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “Team player” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Team player," by B. Devitt. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 18 March 2014Volume 160, Issue 6Page: 440KeywordsBloodDeoxyadenosine monophosphateEmotionsFearLigamentsRunningShockSweat ePublished: 18 March 2014 Issue Published: 18 March 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Reproductive Toxicology of Disinfection By-Products
Authors: M. Kate Smith, Harold Zenick, Emma Lou George
Journal: Environmental Health Perspectives (1986)

The chronic exposure of large segments of the population to disinfected drinking water has necessitated an evaluation of the health effects of the by-products of the chlorination process. This paper reviews the available information concerning the reproductive consequences associated with exposure to disinfection by-products. Four groups of compounds are discussed: the trihalomethanes, in particular chloroform; the chlorinated phenols; chlorinated humic substances; and the haloacetonitriles. In the pregnant female, chloroform and the 2- and 2,4-chlorophenols produced low levels of embryo- and fetotoxicity. Chloroform induced terata when administered by inhalation. The chlorinated humic substances and 2,4,6-trichlorophenol were without significant reproductive effects. The haloacetonitriles showed in utero toxicity, becoming more severe with increasing halogen substitution.
Letter: Diagnostic test for multiple sclerosis.
Authors: M A Crawford, A G Hassam
Journal: BMJ (1975)

Major difference (A) 18 (2-1%) 56 (8 0%)2 (0 7%) Minor difference (B) 41 (4 7%) 77 (11-0%) 12 (4-1%) Total A + B 59 (6-8%) 133 (19-0%) 14 (4-8%) been obtained in all but eight of the first 300 cases reviewed.Differences between the consensus diagnosis and the participants' diagnoses are placed in two categories; (a) a diagnosis that gives a misleading prognosis or one that would lead to inappropriate treatment, and (b) a minor diagnostic difference of no clinical relevance.The consensus diagnosis has been compared also with the original 1970 diagnosis.Nine pathologists participated.These have been divided into two groups, senior pathologists who have obtained the M.R.C.Patih.diploma and junior pathologists without this diploma.The results of the first 300 cases are shown in the table.Since clinical information was minimal and since consultation between pathologists before diagnosis was not permitted, the figures may be interpreted as the maximum for incorrect diagnosis.The benefits of this on.-goingsystem are as follows.(1) It has proved to be a valu- able educational exercise for consultant and trainee pathologists.(2) Uniformity of nomenclature and diagnostic criteria have been promoted.(3) It is a valuable guide to the suitability for delegation of responsibility for reporting.We can see that a comparable system may have advantages in the clinical field.-Weare, etc.,
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.
Authors: Laurence Albiges, Sylvie Negrier, Cécile Dalban, Christine Chevreau, Gwenaelle Gravis, Stephane Oudard, Brigitte Laguerre, Philippe Barthelemy, Delphine Borchiellini, Marine Gross-Goupil, Lionnel Geoffrois, Frederic Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier
Journal: Journal of Clinical Oncology (2019)

542 Background: NIVOREN GETUG AFU 26 study, is a French multicenter prospective study to evaluate safety and efficacy of Nivolumab (N) in a broad “real world setting” in mRCC after failure of 1 or 2 tyrosine kinase inhibitors. Methods: Between February 2016 and June 2017, 729 pts have been enrolled across 27 institutions. Primary objective of the trial was safety assessed by grade ≥ 3 treatment related adverse event (TRAE). Results: Overall, 720 patients treated with N were included in this final analysis. All pts had clear cell mRCC. Median age was 64 years old, 77.4% were male, 84.7% had prior nephrectomy. ECOG PS was &gt;1 in 15.0%, 21.3% pts had received prior everolimus, 22.4% pts had received more than 2 previous lines, IMDC risk groups were 18.3%/56.2%/25.5% for good/intermediate and poor risk respectively. Brain Metastasis at screening was noted in 83 (12.3%) pts. With a median follow up of 20.9 months (mo), median duration of treatment was 5.2 mo (0.5; 28.1) with 15% of pts still on therapy. Median PFS was 3.2 IC 95% [2.9; 4.6] mo. At the time of this analysis, 316 pts have died and 12 mo OS rate was 69% IC 95% [66; 73]. Objective response rate was 20.8% (1.2% CR, 19.6%PR). Stable disease was seen in 31.6% and PD in 47.6%. Noteworthy, 46.1% of pts were treated beyond progression. Overall, 123 pts (17.1%) have presented at least one grade ≥ 3 TRAE, including asthenia (2.4%), metabolic disorders (2.1%), gastro-intestinal disorders (1 .9%), musculoskeletal (1.7%), renal disorders (1.3%), hematologic (1.3%). 6 patients have developed grade 5 toxicity (2 cardiac failure, 1 macrophage activation syndrom, 1 Cerebral hemorrhage, 1 unknown). Treatment discontinuation due to any grade TRAE occurred in 54 pts (7.5%). Interestingly, pts with grade ≥ 3 TRAE had longer PFS than pts without grade ≥ 3 TRAE (HR 0.69 [0.55-0.87]). Conclusions: We report the primary objective analysis of the largest prospective real world setting study of N in mRCC. NIVOREN study demonstrates that N safety and efficacy in a “real world” prospective study are similar to the pivotal study. Grade ≥ 3 TRAE was associated with longer PFS. Clinical trial information: NCT03013335.
Developing a protocol to identify and prioritize research questions for psoriasis: a James Lind Alliance Priority Setting Partnership
Authors: R. Majeed-Ariss, M. McPhee, C. Bundy, C.E.M. Griffiths, H. Young
Journal: British Journal of Dermatology (2018)

Psoriasis is a common condition that affects over two million people in the UK and causes red, flaky patches of skin which can sometimes feel sore or itchy. People with psoriasis can be affected by their disease physically, emotionally and socially. There are many unanswered questions about psoriasis. To find out what the most important questions are, a Psoriasis Priority Setting Partnership PSP is being carried out now. The PSP involves patients, families, carers and healthcare professionals working together to follow a process outlined by the James Lind Alliance. The first step is for all groups with an interest in psoriasis to complete a survey about what they think the important research questions are. Survey responses are then checked against existing evidence. Questions raised in the surveys, but which have already previously been answered, will be shared with relevant organisations who may consider how this information can be better shared with clinicians, patients and their families. Questions raised in the surveys, which have not already been answered will be compiled into a list. This list will be sent round to stakeholders in a second survey where they will be ordered by importance. At a final workshop, a ‘top ten’ list of unanswered questions will be agreed by patients, their carers and health professionals. This ‘top ten’ list will be shared widely with psoriasis researchers and funders, to encourage research that focuses on tackling the key issues which really matter to patients, families, carers and healthcare professionals.